AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19531276
Drug: Self-management plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management plus treatment as usual (TAU) (n=31)
Trial: 19531276
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) control condition (n=33)
Trial: 15824372
Drug: Indinavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir treatment
Trial: 10402766
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin 70 mg/m2 on day 1, fluorouracil 700 mg/m2 and leucovorin 20 mg/m2 on days 1 to 5)
Trial: 10402766
Drug: Surgery (immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery (immediate surgery without chemotherapy)
Trial: 28050801
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg (D4)
Trial: 11093989
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg (D10)
Trial: 21255753
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream during tDCS stimulation
Trial: 18974529
Drug: Inami L‐5110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inami L‐5110 (GATI)
Trial: 17054744
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of mefloquine and artesunate
Trial: 17054744
Drug: New fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New fixed combination of mefloquine and artesunate
Trial: 15189956
Drug: β2-agonist (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β2-agonist (single dose)
Trial: 3777548
Drug: Moderate normovolaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate normovolaemic haemodilution induced with a colloid solution (Plasmion)
Trial: 31461801
Drug: 5 μg dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg dexmedetomidine
Trial: 31461801
Drug: 50 mg MgSO4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg MgSO4
Trial: 27316483
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg twice daily for 6 weeks
Trial: 20353120
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection at Neiguan (PC 6) with 2.5 mg Droperidol (1 mL)
Trial: 20353120
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection with 1 mL Droperidol
Trial: 18718815
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (goserelin and anastrozole or goserelin and tamoxifen)
Trial: 18718815
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy with zoledronic acid (goserelin, anastrozole, and zoledronic acid or goserelin, tamoxifen, and zoledronic acid)
Trial: 18718815
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (without zoledronic acid)
Trial: 12860219
Drug: berberine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: berberine 1.2 to 2.0 g/day
Trial: 11028252
Drug: Intravenous RGD891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous RGD891
Trial: 3899397
Drug: Mefloquine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (1000 mg single oral dose)
Trial: 6360400
Drug: Sulfadoxine-pyrimethamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (2 tablets, each containing 500 mg of sulfadoxine plus 25 mg of pyrimethamine)
Trial: 26398741
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of MenACWY-CRM (ACWY2)
Trial: 26398741
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of placebo followed by 1 dose of MenACWY-CRM (ACWY1)
Trial: 24876616
Drug: Standard pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pump therapy with delayed CGM initiation
Trial: 18971247
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch application
Trial: 3324800
Drug: Saline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline treatment
Trial: 30558984
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with oral ciprofloxacin (2 doses prior to urinary catheter removal)
Trial: 30558984
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibiotics prior to urinary catheter removal)
Trial: 30558984
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with oral ciprofloxacin
Trial: 25183287
Drug: Dexmedetomidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.8 μg kg(‐1) h(‐1))
Trial: 22429618
Drug: Topical mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mydriatics (TM)
Trial: 21425144
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with loop electrical excision procedure (LEEP)
Trial: 17310835
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy by antiandrogens
Trial: 17310835
Drug: Antineoplastic chemotherapeutic
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplastic chemotherapeutic agents such as estramustine and taxanes
Trial: 17310835
Drug: Neoadjuvant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapies including systemic therapy before or after local treatment
Trial: 9672930
Drug: Intramuscular tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tenoxicam 0.75 mg.kg‐1
Trial: 9672930
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine sulphate 0.2 mg.kg‐1
Trial: 31807987
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session
Trial: 30686636
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg for 28 days
Trial: 30686636
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of atorvastatin vs placebo
Trial: 26498129
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (∼14 g day(‐1) NaCl)
Trial: 26498129
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg, non-selective COX-1 and COX-2 inhibitor)
Trial: 26498129
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg, selective COX-2 inhibitor)
Trial: 15553106
Drug: emedastine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emedastine 4 mg o.d.
Trial: 31443735
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (rehabilitation treatment)
Trial: 21324184
Drug: Weekly docetaxel-based
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel-based chemotherapy
Trial: 21324184
Drug: 3-weekly docetaxel-based
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel-based chemotherapy
Trial: 18304128
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 7 micro/kg
Trial: 17699253
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (prednisolone, azathioprine, warfarin, and dipyridamole)
Trial: 17699253
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment and Prednisolone alone
Trial: 12714472
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (spinal mobilisation)
Trial: 12714472
Drug: General practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner care (counselling, education, and drugs)
Trial: 19508590
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion
Trial: 22362401
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) infusion
Trial: 1572459
Drug: No detectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No detectable serum concentration (less than 50 ng ml‐1)
Trial: 16325037
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/day (F group)
Trial: 9484961
Drug: Artemether (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (intramuscular injection)
Trial: 9484961
Drug: Quinine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (intravenous infusion)
Trial: 18617486
Drug: Oral co‐trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co‐trimoxazole
Trial: 25885325
Drug: RTS,S/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E vaccine (0-1-2-month schedule)
Trial: 9174388
Drug: PGE1 treatment
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 treatment (60 micrograms PGE1 in 250 ml of physiological saline, twice daily for 3 weeks)
Trial: 1359619
Drug: AZT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT (300 mg/day) + ACV (600 mg/day)
Trial: 6770673
Drug: Cefaclor (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (20 mg/kg/day for 10 days)
Trial: 25095846
Drug: Kefir drink
RxNorm normalized name: Lentilactobacillus kefiri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir drink (100 ml per day for 2 weeks)
Trial: 19962985
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose
Trial: 22721966
Drug: Exendin(9-39) infusion
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin(9-39) infusion
Trial: 9861862
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B surface antigen (HbsAg) and antibodies to hepatitis B virus (anti‐HBV)
Trial: 2778791
Drug: lisinopril (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (20-40 mg once daily)
Trial: 28832557
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care plus self‐efficacy interventions (health education, behavior therapy, psychological intervention)
Trial: 19749494
Drug: efonidipine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Efonidipine (DB09235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efonidipine hydrochloride ethanolate 40 mg/day
Trial: 19749494
Drug: amlodipine besilate
RxNorm normalized name: Amlodipine besilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine besilate 5 mg/day
Trial: 17093150
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Cuban sugar cane policosanol (SCP) per day
Trial: 15055092
Drug: Placebo-magnetic knee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-magnetic knee sleeve treatment
Trial: 8127283
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg for gastroscopy, 4 mg for colonoscopy)
Trial: 21697747
Drug: Concurrent Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Training (CT)
Trial: 25142085
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate hydration (1-h 250 mL 1.4%)
Trial: 10981820
Drug: Pulsating magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsating magnetic field (induction: 25-80 microT; frequency: 200 Hz) applied for 3 weeks (5 days/week, twice a day for 8 minutes each)
Trial: 8814695
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in disseminated disease (Ann Arbor stage III)
Trial: 1706244
Drug: beta-hCG vaccine
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-hCG vaccine formulations
Trial: 20935058
Drug: 1 day
RxNorm normalized name: ZonaCort 11 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 day of 0.25 mg palonosetron
Trial: 20935058
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of 0.25 mg palonosetron
Trial: 20935058
Drug: 2 days
RxNorm normalized name: Chapstick 12 Days of Christmas KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of 0.25 mg palonosetron
Trial: 19840579
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of clopidogrel for 30 days (group II)
Trial: 16938749
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin (intended INR 1.3-1.9)
Trial: 9363869
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no warfarin)
Trial: 18208828
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin
Trial: 11990165
Drug: Albuterol administered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered via Rotahaler at various altitudes
Trial: 31881995
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) specific for LLD, delivered in 15 sessions over 8 weeks (twice per week) with a 6-month follow-up period.
Trial: 31881995
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) specific for LLD.
Trial: 30387904
Drug: Pimavanserin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin with cognitive-enhancing medication
Trial: 30387904
Drug: Pimavanserin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin without cognitive-enhancing medication
Trial: 24121917
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (G1)
Trial: 11340105
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral stimulation
Trial: 9862944
Drug: Atovaquone (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone (1500 mg daily)
Trial: 1098594
Drug: Quinestrol 2
RxNorm normalized name: quinestrol
DrugBank: Quinestrol (DB04575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinestrol 2 mg
Trial: 21723606
Drug: Linagliptin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 0.5 mg
Trial: 21333984
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone
Trial: 16490616
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/d plus ezetimibe 10 mg/d
Trial: 10885234
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg.kg‐1 intravenous bolus injection followed by 6 mg.kg‐1.h‐1 infusion)
Trial: 10885234
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg.kg‐1 intravenous bolus injection followed by 1 mg.kg‐1.h‐1 infusion)
Trial: 10885234
Drug: Fentanyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (5 micrograms.kg‐1 injection)
Trial: 6441958
Drug: Vasopressin treatment
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin treatment
Trial: 18653315
Drug: Carrot juice
RxNorm normalized name: carrot juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot juice (330 mL daily)
Trial: 15504308
Drug: Rabeprazole (RAB)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RAB) 10 mg
Trial: 23829508
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg)
Trial: 29316931
Drug: Novel multi-component
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel multi-component fortifier and protein supplement derived from donkey milk
Trial: 29316931
Drug: Control bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control bovine milk-based multicomponent fortifier and protein supplement
Trial: 21206546
Drug: Ramelteon 8
RxNorm normalized name: ramelteon 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg (n = 8)
Trial: 8842657
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg kg‐1 i.v. bolus, followed by continuous infusion (15 patients)
Trial: 6130295
Drug: Red-cell suspension
RxNorm normalized name: RED CELL TAGGING KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red-cell suspension in SAGM medium
Trial: 31727361
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10)
Trial: 31727361
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg combined with Ezetimibe 10 mg (R10 + E10)
Trial: 25847819
Drug: 3-dimensional conformal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dimensional conformal radiation therapy (3D-CRT)
Trial: 24346989
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
Trial: 7128838
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 6 months
Trial: 21304215
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg combined with ezetimibe 10 mg (F20/E10)
Trial: 7489937
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg daily
Trial: 8071301
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment with clinician's choice, including continued phenelzine and combination with amitriptyline
Trial: 8071301
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment with clinician's choice, including a variety of other treatments
Trial: 3189898
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 1 mg
Trial: 7008655
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 2 mg
Trial: 3377948
Drug: i.v. morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. morphine 30 mg
Trial: 25735497
Drug: Ramosetron 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.6 mg mixed with PCA (RPCA group)
Trial: 25735497
Drug: Palonosetron 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 75 μg (P group)
Trial: 25735497
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg (R0.3 group)
Trial: 21705068
Drug: Diet intervention
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet intervention (dietary consultation every 3 months with monthly nurse support)
Trial: 21705068
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus activity intervention (dietary consultation every 3 months with monthly nurse support plus a pedometer-based activity programme)
Trial: 16981967
Drug: Once-daily urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily urokinase (5000-6000 IU/kg/dose)
Trial: 8281243
Drug: Fluoxetine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (80 mg/day)
Trial: 9286186
Drug: Phenelzine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine (60 mg/day)